Benzinga | Oct 19, 2020 08:00AM EDT

BrainStorm To Present NurOwn Exosome Preclinical ARDS Outcomes At Virtual New York Stem Cell Foundation Conference Oct. 20

NEW YORK, Oct. 19, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced the presentation of a poster titled, "MSC-NTF (NurOwn(r)) Exosomes: A Novel Therapeutic Modality in the Mouse LPS-induced ARDS model Analysis" at the NYSCF Conference Meeting, being held virtually. The scientific poster will be presented on October 20.

POSTER HIGHLIGHTS:

* One of the most severe complications of the current COVID-19 pandemic is acute respiratory distress syndrome (ARDS). ARDS is caused by increased amounts of pro-inflammatory cytokines, leading to lung damage and loss of lung function.

* Results from a study in a mouse model of lipopolysaccharide (LPS)-induced ARDS showed that intratracheal administration of NurOwn (MSC-NTF cells) derived exosomes resulted in a statistically significant improvement in multiple lung parameters. These included the clinically relevant factors: functional lung recovery, reduction in pro-inflammatory cytokines and attenuation of lung damage.

* These positive preclinical results suggest that MSC-NTF exosomes may be suitable as a therapy for COVID-19 induced ARDS, and are more effective at combatting ARDS physiological, pathological, and biochemical symptoms than exosomes isolated from non-induced MSCs.

"Brainstorm continues to explore the full potential of our proprietary platform cell technology and we are very proud of the therapeutic pipeline advances made by our scientific teams," said Chaim Lebovits, CEO of Brainstorm, "At the same time we remain fully focused on delivering top-line data for our pivotal phase 3 ALS clinical trial as planned and completing the necessary activities to submit a BLA following data review."